The ecology of cancer from an evolutionary game theory perspective
暂无分享,去创建一个
[1] Josef Hofbauer,et al. Evolutionary Games and Population Dynamics , 1998 .
[2] G. Roodman. Pathogenesis of myeloma bone disease , 2009, Journal of cellular biochemistry.
[3] M. Elmantaser,et al. Secondary osteoporosis. , 2009, Endocrine development.
[4] T. Kunkel,et al. DNA replication fidelity. , 1992, The Journal of biological chemistry.
[5] John Cairns,et al. Mutation selection and the natural history of cancer , 1975, Nature.
[6] J M Smith,et al. Evolution and the theory of games , 1976 .
[7] B. Barlogie,et al. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. , 2008, Bone.
[8] Gordon My,et al. Routes to repopulation--a unification of the stochastic model and separation of stem-cell subpopulations. , 1994 .
[9] E. Terpos,et al. New insights into the pathophysiology and management of bone disease in multiple myeloma , 2003, British journal of haematology.
[10] F. C. Santos,et al. Risk of collective failure provides an escape from the tragedy of the commons , 2011, Proceedings of the National Academy of Sciences.
[11] F. Craig,et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. , 2000, Blood.
[12] I. Holen,et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. , 2001, Blood.
[13] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[14] Lucio Luzzatto,et al. The use of PIG-A as a sentinel gene for the study of the somatic mutation rate and of mutagenic agents in vivo. , 2010, Mutation research.
[15] X. Mariette,et al. The High Rate of Bone Resorption in Multiple Myeloma is due to RANK (Receptor Activator of Nuclear Factor-κB) and RANK Ligand Expression , 2004, Leukemia & lymphoma.
[16] K. Kinzler,et al. Cancer genes and the pathways they control , 2004, Nature Medicine.
[17] A. Traulsen,et al. Explaining the in vitro and in vivo differences in leukemia therapy , 2011, Cell cycle.
[18] Francisco C. Santos,et al. A bottom-up institutional approach to cooperative governance of risky commons , 2013 .
[19] F. C. Santos,et al. Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells , 2009, British Journal of Cancer.
[20] M. Dimopoulos,et al. Myeloma bone disease and proteasome inhibition therapies. , 2007, Blood.
[21] Arne Traulsen,et al. (A)Symmetric Stem Cell Replication and Cancer , 2007, PLoS Comput. Biol..
[22] K. Moriyama,et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. , 2004, Blood.
[23] A. Traulsen,et al. Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells , 2009, Haematologica.
[24] G. Morgan,et al. Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment , 2013, Clinical Cancer Research.
[25] J. Epstein,et al. Consequences of interactions between the bone marrow stroma and myeloma. , 2003, The hematology journal : the official journal of the European Haematology Association.
[26] Bart Barlogie,et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. , 2007, Blood.
[27] C. Dinarello. Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease. , 2009, Mayo Clinic proceedings.
[28] R. Kyle,et al. Drug therapy: Multiple myeloma , 2004 .
[29] G. Roodman,et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. , 2001, The Journal of clinical investigation.
[30] J. Berenson. Bone disease in myeloma , 2001, Current treatment options in oncology.
[31] Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. , 2008, Blood.
[32] Jorge M. Pacheco,et al. Compartmental Architecture and Dynamics of Hematopoiesis , 2007, PloS one.
[33] M. Roizen,et al. Hallmarks of Cancer: The Next Generation , 2012 .
[34] P. L. Bergsagel,et al. Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] R. Kyle,et al. Multiple myeloma. , 2008, Blood.
[36] Lucio Luzzatto,et al. A quantitative measurement of the human somatic mutation rate. , 2005, Cancer research.
[37] D. Jelinek,et al. Mechanisms of myeloma cell growth control. , 1999, Hematology/oncology clinics of North America.
[38] T. Weber,et al. SECONDARY OSTEOPOROSIS : Diagnostic Considerations , 1998 .
[39] L. Melton,et al. Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUS. , 2011, Blood.
[40] Arne Traulsen,et al. Somatic mutations and the hierarchy of hematopoiesis , 2010, BioEssays : news and reviews in molecular, cellular and developmental biology.
[41] A. Traulsen,et al. Chronic Myeloid Leukemia: Origin, Development, Response to Therapy, and Relapse , 2008 .
[42] R. Fonseca,et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. , 2012, Blood.
[43] P. L. Bergsagel,et al. Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.
[44] G. Roodman,et al. Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease , 2001 .
[45] A. Traulsen,et al. Reproductive fitness advantage of BCR-ABL expressing leukemia cells. , 2010, Cancer letters.
[46] T. Kunkel. DNA Replication Fidelity* , 2004, Journal of Biological Chemistry.
[47] Jorge M Pacheco,et al. Acquired hematopoietic stem-cell disorders and mammalian size. , 2007, Blood.
[48] L. Imhof,et al. Stochasticity and evolutionary stability. , 2006, Physical review. E, Statistical, nonlinear, and soft matter physics.
[49] J. Shaughnessy,et al. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. , 2008, Blood.
[50] Peter Guttorp,et al. Evidence that hematopoiesis may be a stochastic process in vivo , 1996, Nature Medicine.
[51] O. Stephens,et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. , 2008, Blood.
[52] Toshio Matsumoto,et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)‐1α and MIP‐1β correlates with lytic bone lesions in patients with multiple myeloma , 2004, British journal of haematology.
[53] N. Raje,et al. Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma , 2011, Clinical Cancer Research.
[54] G. Roodman. Erratum to ?Pathogenesis of myeloma bone disease? 6Blood Cells Mol. Dis. 32 (2004) 290?2929 , 2004 .
[55] M. Junttila,et al. Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.
[56] G. Roodman,et al. Role of the Bone Marrow Microenvironment in Multiple Myeloma , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[57] Trevor J Pugh,et al. Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.
[58] Natalia L. Komarova,et al. Computational Biology of Cancer: Lecture Notes and Mathematical Modeling , 2005 .
[59] N. Komarova,et al. Symmetric vs. Asymmetric Stem Cell Divisions: An Adaptation against Cancer? , 2013, PloS one.
[60] Wei Zhang,et al. Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. , 2014, Blood.
[61] A. Dispenzieri,et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. , 2009, Mayo Clinic proceedings.
[62] C. Dinarello,et al. Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.